Detection and quantitation of afucosylated N-linked oligosaccharides in recombinant monoclonal antibodies using enzymatic digestion and LC-MS
- PMID: 22569911
- DOI: 10.1007/s13361-012-0397-8
Detection and quantitation of afucosylated N-linked oligosaccharides in recombinant monoclonal antibodies using enzymatic digestion and LC-MS
Abstract
The presence of N-linked oligosaccharides in the CH2 domain has a significant impact on the structure, stability, and biological functions of recombinant monoclonal antibodies. The impact is also highly dependent on the specific oligosaccharide structures. The absence of core-fucose has been demonstrated to result in increased binding affinity to Fcγ receptors and, thus, enhanced antibody-dependent cellular cytotoxicity (ADCC). Therefore, a method that can specifically determine the level of oligosaccharides without the core-fucose (afucosylation) is highly desired. In the current study, recombinant monoclonal antibodies and tryptic peptides from the antibodies were digested using endoglycosidases F2 and H, which cleaves the glycosidic bond between the two primary GlcNAc residues. As a result, various oligosaccharides of either complex type or high mannose type that are commonly observed for recombinant monoclonal antibodies are converted to either GlcNAc residue only or GlcNAc with the core-fucose. The level of GlcNAc represents the sum of all afucosylated oligosaccharides, whereas the level of GlcNAc with the core-fucose represents the sum of all fucosylated oligosaccharides. LC-MS analysis of the enzymatically digested antibodies after reduction provided a quick estimate of the levels of afucosylation. An accurate determination of the level of afucosylation was obtained by LC-MS analysis of glycopeptides after trypsin digestion.
Similar articles
-
Methods to determine the level of afucosylation in recombinant monoclonal antibodies.Anal Chem. 2010 Dec 1;82(23):9871-7. doi: 10.1021/ac102332f. Epub 2010 Nov 8. Anal Chem. 2010. PMID: 21058685
-
LC-MS analysis of glycopeptides of recombinant monoclonal antibodies by a rapid digestion procedure.J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Oct 15;907:87-93. doi: 10.1016/j.jchromb.2012.09.004. Epub 2012 Sep 18. J Chromatogr B Analyt Technol Biomed Life Sci. 2012. PMID: 23036907
-
Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.Glycobiology. 2007 Jan;17(1):104-18. doi: 10.1093/glycob/cwl057. Epub 2006 Sep 29. Glycobiology. 2007. PMID: 17012310
-
Impact of IgG Fc-Oligosaccharides on Recombinant Monoclonal Antibody Structure, Stability, Safety, and Efficacy.Biotechnol Prog. 2017 Sep;33(5):1173-1181. doi: 10.1002/btpr.2498. Epub 2017 Jun 12. Biotechnol Prog. 2017. PMID: 28547754 Review.
-
Strategies for controlling afucosylation in monoclonal antibodies during upstream manufacturing.Biotechnol J. 2023 Jul;18(7):e2200604. doi: 10.1002/biot.202200604. Epub 2023 Apr 19. Biotechnol J. 2023. PMID: 37029472 Review.
Cited by
-
Development of orally active inhibitors of protein and cellular fucosylation.Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):5404-9. doi: 10.1073/pnas.1222263110. Epub 2013 Mar 14. Proc Natl Acad Sci U S A. 2013. PMID: 23493549 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous